Katie Lynn Hammer1, Julie Ann Justo2, P Brandon Bookstaver2, Joseph Kohn3, Helmut Albrecht4, Majdi N Al-Hasan4. 1. Department of Clinical Pharmacy, Carolinas HealthCare System, Charlotte, NC, USA. Electronic address: Katie.Hammer@carolinashealthcare.org. 2. Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA; Department of Pharmacy, Palmetto Health Richland, Columbia, SC, USA. 3. Department of Pharmacy, Palmetto Health Richland, Columbia, SC, USA. 4. Department of Medicine, Division of Infectious Diseases, University of South Carolina School of Medicine, Columbia, SC, USA.
Abstract
OBJECTIVE: This retrospective case-control study examines risk factors for bloodstream infections (BSI) due to Pseudomonas aeruginosa (PSA). METHODS: Hospitalized adults with Gram-negative BSI at Palmetto Health from 2010 to 2015 were identified. Multivariate logistic regression was used to examine PSA BSI risk factors. RESULTS: Seventy and 910 patients with PSA and Enterobacteriaceae BSI, respectively, were included. Prior use of β-lactams (adjusted odds ratio [aOR] 3.9, 95% confidence intervals [CI]: 2.3-6.9), but not fluoroquinolones (aOR 1.0, 95% CI: 0.4-2.2), was a risk factor for PSA BSI. Immune compromised status (aOR 3.7, 95% CI: 2.0-6.7), respiratory source (aOR 4.4, 95% CI: 2.1-8.9), and prolonged hospitalization (aOR 1.9, 95% CI: 1.1-3.5), were predictors of PSA BSI. CONCLUSIONS: Determination of class of previously used antibiotics among other clinical variables helps identify patients at risk of PSA BSI and offers opportunities to optimize empirical antimicrobial therapy.
OBJECTIVE: This retrospective case-control study examines risk factors for bloodstream infections (BSI) due to Pseudomonas aeruginosa (PSA). METHODS: Hospitalized adults with Gram-negative BSI at Palmetto Health from 2010 to 2015 were identified. Multivariate logistic regression was used to examine PSA BSI risk factors. RESULTS: Seventy and 910 patients with PSA and Enterobacteriaceae BSI, respectively, were included. Prior use of β-lactams (adjusted odds ratio [aOR] 3.9, 95% confidence intervals [CI]: 2.3-6.9), but not fluoroquinolones (aOR 1.0, 95% CI: 0.4-2.2), was a risk factor for PSA BSI. Immune compromised status (aOR 3.7, 95% CI: 2.0-6.7), respiratory source (aOR 4.4, 95% CI: 2.1-8.9), and prolonged hospitalization (aOR 1.9, 95% CI: 1.1-3.5), were predictors of PSA BSI. CONCLUSIONS: Determination of class of previously used antibiotics among other clinical variables helps identify patients at risk of PSA BSI and offers opportunities to optimize empirical antimicrobial therapy.
Authors: Sarah E Battle; Matthew R Augustine; Christopher M Watson; P Brandon Bookstaver; Joseph Kohn; William B Owens; Larry M Baddour; Majdi N Al-Hasan Journal: Infection Date: 2019-02-08 Impact factor: 3.553
Authors: Elizabeth B Nimmich; P Brandon Bookstaver; Joseph Kohn; Julie Ann Justo; Katie L Hammer; Helmut Albrecht; Majdi N Al-Hasan Journal: Hosp Pharm Date: 2017-07-21
Authors: Mohammed J Al-Jaghbeer; Julie Ann Justo; William Owens; Joseph Kohn; P Brandon Bookstaver; Jennifer Hucks; Majdi N Al-Hasan Journal: Infection Date: 2018-05-11 Impact factor: 3.553